Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy

Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers, yet not all patients respond. We report the evaluation of >300 patient samples across 22 tumor types from four KEYNOTE clinica...

Full description

Saved in:

Bibliographic Details
Published in:	Science (American Association for the Advancement of Science) Vol. 362; no. 6411
Main Authors:	Cristescu, Razvan, Mogg, Robin, Ayers, Mark, Albright, Andrew, Murphy, Erin, Yearley, Jennifer, Sher, Xinwei, Liu, Xiao Qiao, Lu, Hongchao, Nebozhyn, Michael, Zhang, Chunsheng, Lunceford, Jared K, Joe, Andrew, Cheng, Jonathan, Webber, Andrea L, Ibrahim, Nageatte, Plimack, Elizabeth R, Ott, Patrick A, Seiwert, Tanguy Y, Ribas, Antoni, McClanahan, Terrill K, Tomassini, Joanne E, Loboda, Andrey, Kaufman, David
Format:	Journal Article
Language:	English
Published:	United States 12.10.2018
Subjects:	Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Biomarkers, Tumor - genetics Cell Cycle Checkpoints Genetic Markers Humans Immunotherapy Inflammation - genetics Molecular Targeted Therapy - methods Mutation Neoplasms - genetics Neoplasms - therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors T-Lymphocytes - immunology Transcriptome Tumor Burden - genetics
ISSN:	1095-9203, 1095-9203
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!